ASCO 2019 | Patient impact: development of drugs to treat METex14 alterations

Paul Paik

Paul Paik, MD, of the Memorial Sloan Kettering Cancer Center, New York, NY, discusses how the development of drugs to treat METex14 alterations may impact lung cancer patients. This interview was recorded at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Share this video  
Similar topics
Related videos
0:48
The LUNAR study: TTFields for NSCLC
Ori Farber
0:55
Tumor treating fields as an anti-mitotic therapy
Ori Farber
1:04
Tepotinib: advanced non-small cell lung cancer
Paul Paik
0:53
Future treatment options for squamous cell lung cancer
Paul Paik
0:55
Squamous cell lung cancer: gene targets
Paul Paik
Lung Cancer
ASCO 2019
Interview
3rd June 2019
More from Paul Paik
Future treatment options for squamous cell lung cancer
Tepotinib: advanced non-small cell lung cancer
Squamous cell lung cancer: gene targets
vjoncology logo VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJO needs the contact information you provide to inform you about our latest oncology news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJOncology is intended for healthcare professionals